Nasdaq · Healthcare
PALVELLA THERAPEUTICS, INC. (PVLA)
As-reported financials and recent SEC filings for PALVELLA THERAPEUTICS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
—
Net income
$-41.7M
Net margin
—
Diluted EPS
$-3.71
ROE
-149.1%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $42.8M | $25.9M | $31.4M |
| Gross profit | — | — | — | — | — |
| Operating income | $-38.6M | $-14.1M | $-11.9M | $-43.5M | $-51.8M |
| Net income | $-41.7M | $-17.4M | $18.7M | $-33.3M | $-45.7M |
| Diluted EPS | $-3.71 | $-1.57 | $0.43 | — | $-5.82 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-07-01
View on EDGAR →32026-07-01
View on EDGAR →8-K2026-06-30
View on EDGAR →42026-06-22
View on EDGAR →1442026-06-17
View on EDGAR →42026-06-16
View on EDGAR →8-K2026-06-16
View on EDGAR →42026-06-12
View on EDGAR →Largest Healthcare peers
Go deeper on PVLA
Search PALVELLA THERAPEUTICS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.